STAA compared with LCTX: revenue, margins and what each company keeps, and the suppliers and customers both name

STAAStaar Surgical Co

Mkt capRevenueRevenue

LCTXLineage Cell Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

STAAStaar Surgical Co

LCTXLineage Cell Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

STAA

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±10.0%▼−1.66%×0.17

Q2 FY26±10.2%▼−0.31%×0.03

May 14 '26±5.1%▲+8.88%×1.75

Q1 FY26±17.0%▲+1.59%×0.09

LCTX1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−2.65%—

= impliedSTAA realized, solidLCTX realized, hatchedOne scale, both sides: full bar = 17%× = |realized| ÷ impliedSource: market data

STAAStaar Surgical Co

25.19▼−5.73%· post 25.19

Mkt cap$1.3BRevenue$83MQ3 FY26Revenue$239MFY25

LCTXLineage Cell Therapeutics, Inc.

0.99▲+0.21%· post 1.01

ClosedNov 6 '26

Mkt cap$258.0MRevenue$1MQ2 FY26Revenue$15MFY25

Compare

ClosedNov 6 '26

STAAStaar Surgical Co

LCTXLineage Cell Therapeutics, Inc.

25.19▼−5.73%post 25.19

Price

0.99▲+0.21%post 1.01

$1.3B

Mkt cap

$258.0M

Q3 FY26$83M

Revenue

$1MQ2 FY26

FY25$239M

Revenue

$15MFY25

STAA25.19▼−5.73%vsLCTX0.99▲+0.21%ClosedNov 6 '26